Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone metastases | IND Approval | CN | 12 Jan 2022 | |
Bone metastases | IND Approval | CN | 12 Jan 2022 | |
Giant Cell Tumor of Bone | IND Approval | CN | 12 Jan 2022 | |
Giant Cell Tumor of Bone | IND Approval | CN | 12 Jan 2022 | |
Multiple Myeloma | IND Approval | CN | 12 Jan 2022 | |
Multiple Myeloma | IND Approval | CN | 12 Jan 2022 |